A case of diffuse scleroderma successfully treated with high-dose intravenous immune globulin infusion [5]

Rheumatology

Volumn 44, Issue 6, 2005, Pages 824-826

  Asano, Y ^a   Ihn, H ^a   Asashima, N ^a   Yazawa, N ^a   Mimura, Y ^a   Jinnin, M ^a   Yamane, K ^a   Tamaki, K ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERSTITIAL COLLAGENASE; MINOCYCLINE; PENICILLAMINE; PROCOLLAGEN; PROTEIN ANTIBODY; TRANSFORMING GROWTH FACTOR BETA RECEPTOR;

CLINICAL FEATURE; DIFFUSE SCLERODERMA; DRUG MECHANISM; DRUG MEGADOSE; HUMAN; IMMUNOMODULATION; LABORATORY TEST; LETTER; LUNG FIBROSIS; PRIORITY JOURNAL; RAYNAUD PHENOMENON; SKIN BIOPSY; TREATMENT OUTCOME; CASE REPORT; CELL CULTURE; DRUG ADMINISTRATION; DRUG EFFECT; FEMALE; FIBROBLAST; MIDDLE AGED;

CELLS, CULTURED; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBROBLASTS; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MIDDLE AGED; SCLERODERMA, DIFFUSE;

EID: 24944505700     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh600     Document Type: Letter

References (8)

1. Clements PJ, Lachenbruch PA, Seibold JR et al. Skin thickness score in systemic sclerosis: An assessment of interobserver variability in 3 independent studies. J Rheumatol 1993;20:1892-6.
2. Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Impaired Smad7-Smurf-mediated negative regulation of transforming growth factor (TGF)-β signaling in scleroderma fibroblasts. J Clin Invest 2004; 113:253-64.
3. Kawakami T, Ihn H, Xu W, Smith E, LeRoy C, Trojanowska M. Increased expression of TGF-β receptors by scleroderma fibroblasts: Evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype. J Invest Dermatol 1998;110:47-51.
4. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor-β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts. Association with increased expression of transforming growth factor-β receptors. Arthritis Rheum 2001;44:474-80.
5. Boletis JN, Aloannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354:569-70.
6. Cherin P, Herson S, Wechsler B et al. Intravenous immunoglobulin for polymyositis and dermatomyositis. Lancet 1990;336:116.
7. Levy Y, Sherer Y, Langevitz P et al. Skin score decrease in systemic sclerosis patients treated with intravenous immunoglobulin - a preliminary report. Clin Rheumatol 2000;19:207-11.
8. Ballow M. Mechanisms of action of intravenous immune serum globulin in autoimmune and inflammatory diseases. J Allergy Clin Immunol 1997;100:151-7.